Navigation Links
Antipsychotic Drug Controls Some Symptoms in Autism Disorder

Risperidone, a drug used to control schizophrenia symptoms, may also help treat behaviors found in autism spectrum disorder, according to a new review of studies.//

The reviewers looked at three randomized, placebo-controlled studies of risperidone (Risperdal) involving 211 participants, including 31 adults.

“[We found] that risperidone may be beneficial for various aspects of autism including irritability, repetition and hyperactivity,” said researchers led by Dr. Ora Jesner of the University of Bristol, in England. But the drug’s benefits may be offset by its side effects, with weight gain the most prominent.

Often diagnosed within the first three years of life, autism spectrum disorder leads to difficulties with social relationships, language and communication skills. Symptoms include withdrawal from social interactions, irritability, problems communicating and repetitive behaviors.

It is known as a “spectrum” disorder because there is a wide variation in how it affects individuals. Figures from the U.S. Centers for Disease Control and Prevention show that as many as 1.5 million Americans may have some form of the disorder.

“Autism spectrum disorder affects many families worldwide,” Jesner said. “At present many of the interventions available are not evidence-based.” He said he and co-author Dr. Mehrnoosh Aref-Adib “wanted to analyze the evidence for one important antipsychotic [drug] used for the condition.”

The review appears in the latest issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

Because of the small number of studies, wide range of different scales used to assess outcomes and sizes of the trials themselves, the research ers were only able to look at how well the patients responded for the three specific symptoms of irritability, repetitive movement and social withdrawal.

In addition to weight gain, significant side effects included involuntary muscle movements. As the studies were of short duration, long-term side effects and usefulness remain unknown. Since risperidone does not cure the disorder and may have to be continued for a long period of time, this is an important missing piece.

Susan Levy, M.D., director of the Regional Autism Center at The Children’s Hospital of Philadelphia, said that the authors’ weak support for the medication in the conclusion surprised her.

“The researchers seemed to be lukewarm towards their positive findings,” said Levy, who was not involved with the study. “From my personal experience, this medication can be quite helpful for behavioral difficulties.”

The Cochrane reviewers and Levy stress that parents and caregivers should be careful about expecting too much from the medication when talking about this treatment with their doctors. Not all behavioral problems can be helped with risperidone and both side effects and improvements from the drug should be considered.

“As ASD is diagnosed at a young age and these short trials lack long-term data, parents or caregivers need to be aware it is not known how long the medication needs to be continued — potentially for a lifetime,” the researchers said. “This is particularly important given the side effects.”

Levy termed risperidone “a more serious medication” that she would reserve for more serious difficulties.

“It needs to be stressed to the parents and others that this is not a cure for autism or for the core symptoms of ASD,” Levy said. “But it works well for some of the associated problems.” Source-Newswise

Related medicine news :

1. Antipsychotic Drug Linked to Pulmonary Embolism
2. New Antipsychotic Medications have Little Advantage Over Older Drugs
3. Antipsychotics – not effective in treating Alzheimer
4. No Evidence to Support Many Off-label Uses of Atypical Antipsychotics
5. Scientists Uncover Cause of Antipsychotic Drug Weight Gain
6. Study Sheds Light on Value of Newer Antipsychotic Drugs for Schizophrenia
7. Scientists Discover Hormone That Controls Hunger
8. Brain behind the Brawn: Vital Molecule in the Brain Controls Appetite
9. Stronger Quadricep Controls Knee Osteoarthritis
10. Pair of MicroRNA Molecules Controls Major Oncogene in Most Common Leukemia
11. Molecular ‘On/Off Switch’ Controls Immune Defenses Against Viruss
Post Your Comments:

(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology: